Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

EU Medicines Agency Reverses Course on Eli Lilly's Alzheimer Drug

Summary by EURACTIV
The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects

5 Articles

Svenska DagbladetSvenska Dagbladet
Lean Right

Turnaround Regarding New Alzheimer's Drug

The European Medicines Agency (EMA) is changing its mind and is now recommending that the EU Commission approve the drug Kisunla for early Alzheimer's disease, reports Läkartidningen.

·Stockholm, Sweden
Read Full Article
EURACTIVEURACTIV
Lean Left

EU medicines agency reverses course on Eli Lilly's Alzheimer drug

The EU's medicines regulator said it would approve the treatment for a limited group of patients, citing concerns over side effects

·Brussels, Belgium
Read Full Article
Time NewsTime News

New Twice-Yearly Injectable Drug Recommended for HIV Prevention in Europe

BRUSSELS — A groundbreaking twice-yearly injectable drug to prevent HIV has received a recommendation for authorization… The post EU Approves Injectable HIV Drug to Combat Transmission appeared first on TIme News.

Read Full Article
Deník.czDeník.cz

European Agency Gives Green Light to Hiv Prevention Drug Being Developed by Czech Scientist

The European Medicines Agency (EMA) has recommended approval of an HIV prevention injection from the American company Gilead Sciences, whose vice president is Czech virologist and biochemist Tomáš Cihlář. The drug, which is administered twice a year, is highly effective, according to the EMA.

Read Full Article
endpoints.newsendpoints.news

CHMP backs Lilly’s Alzheimer’s drug in certain patients, Gilead’s twice-yearly HIV prevention shot, among others

CHMP endorses 13 new medicines including Lilly's Alzheimer's drug Kisunla and Gilead's HIV preventive lenacapavir, while rejecting three drugs including Sarepta's Elevidys.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources lean Left, 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

endpoints.news broke the news in on Friday, July 25, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Alzheimer's Disease icon

Alzheimer's Disease

HIV icon

HIV

Alzheimer's Disease icon

Alzheimer's Disease

Eli Lilly icon

Eli Lilly

European Union icon

European Union

Gilead Sciences icon

Gilead Sciences

Medical icon

Medical

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal